Literature DB >> 26909818

Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation.

Rochelle Sweis1, José Biller2.   

Abstract

OPINION STATEMENT: Anticoagulation remains the optimal treatment choice for secondary stroke prevention of AF. The vitamin K antagonists (VKAs) have been the choice of treatment for the last 60 years, but the new oral anticoagulants are now a safe option for treatment of non-valvular AF (NVAF) in the right patient population, taking into account age, renal function, bleeding risk, cardiovascular comorbidities, cost, and drug interactions.

Entities:  

Keywords:  Atrial fibrillation; NOACs; Stroke; Vitamin K antagonists

Year:  2016        PMID： 26909818     DOI： 10.1007/s11936-016-0446-x

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN： 1092-8464


  50 in total

Review 1.  Regional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy.

Authors:  T T Horlocker
Journal:  Br J Anaesth       Date:  2011-12       Impact factor: 9.166

2.  New options in anticoagulation for atrial fibrillation.

Authors:  Gregory J del Zoppo; Misha Eliasziw
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

3.  How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society.

Authors:  David J Gladstone; William H Geerts; James Douketis; Noah Ivers; Jeff S Healey; Kori Leblanc
Journal:  Ann Intern Med       Date:  2015-09-01       Impact factor: 25.391

Review 4.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

5.  Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

Authors:  Amitava Banerjee; Deirdre A Lane; Christian Torp-Pedersen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

6.  Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Lewis B Morgenstern; J Claude Hemphill; Craig Anderson; Kyra Becker; Joseph P Broderick; E Sander Connolly; Steven M Greenberg; James N Huang; R Loch MacDonald; Steven R Messé; Pamela H Mitchell; Magdy Selim; Rafael J Tamargo
Journal:  Stroke       Date:  2010-07-22       Impact factor: 7.914

7.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Gregory Y H Lip; Jesper Lindhardsen; Deirdre A Lane; Ole Ahlehoff; Morten Lock Hansen; Jakob Raunsø; Janne Schurmann Tolstrup; Peter Riis Hansen; Gunnar Hilmar Gislason; Christian Torp-Pedersen
Journal:  Thromb Haemost       Date:  2011-07-20       Impact factor: 5.249

8.  Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.

Authors:  Saurav Chatterjee; Partha Sardar; Jay S Giri; Joydeep Ghosh; Debabrata Mukherjee
Journal:  Mayo Clin Proc       Date:  2014-07       Impact factor: 7.616

9.  The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.

Authors:  Stuart J Connolly; Lars Wallentin; Michael D Ezekowitz; John Eikelboom; Jonas Oldgren; Paul A Reilly; Martina Brueckmann; Janice Pogue; Marco Alings; John V Amerena; Alvaro Avezum; Iris Baumgartner; Andrzej J Budaj; Jyh-Hong Chen; Antonio L Dans; Harald Darius; Giuseppe Di Pasquale; Jorge Ferreira; Greg C Flaker; Marcus D Flather; Maria Grazia Franzosi; Sergey P Golitsyn; David A Halon; Hein Heidbuchel; Stefan H Hohnloser; Kurt Huber; Petr Jansky; Gabriel Kamensky; Matyas Keltai; Sung Soon Kim; Chu-Pak Lau; Jean-Yves Le Heuzey; Basil S Lewis; Lisheng Liu; John Nanas; Razali Omar; Prem Pais; Knud E Pedersen; Leopoldo S Piegas; Dimitar Raev; Pal J Smith; Mario Talajic; Ru San Tan; Supachai Tanomsup; Lauri Toivonen; Dragos Vinereanu; Denis Xavier; Jun Zhu; Susan Q Wang; Christine O Duffy; Ellison Themeles; Salim Yusuf
Journal:  Circulation       Date:  2013-06-14       Impact factor: 29.690

10.  Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2 DS2 -VASc score of 1.

Authors:  Duo Huang; Luo Anguo; Wen-Sheng Yue; Lixue Yin; Hung-Fat Tse; Chung-Wah Siu
Journal:  Pacing Clin Electrophysiol       Date:  2014-07-16       Impact factor: 1.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.